Protalix Says Gaucher Drug Met Goals In Trial

NEW YORK (AP) — Protalix BioTherapeutics Inc. said Thursday a late-stage study of its Gaucher disease drug met its primary goals.

The company said patients taking Uplyso had significantly smaller spleen volume, which is a symptom of Gaucher disease, a rare enzyme disorder that can cause liver and neurological problems. Patients also had greater hemoglobin levels and decreased liver size, Protalix said.

Shares of Protalix climbed 71 cents, or 8 percent, to $9.59 in afternoon trading after earlier setting an annual high of $9.89.

The study tested two doses of intravenous Uplyso on 31 patients around the world.

Patients in the nine-month trial received a dose of Uplyso every two weeks. The doses were either 30 milligrams per kilogram of the patient's body weight, or 60 milligrams per kilogram. Protalix said both patient groups had significantly lower spleen volumes after six months of treatment.

Protalix said patients who received the larger dose had a significant improvement in blood platelet counts. Patients who were given the smaller dose also had higher blood platelet levels, but the improvement was not statistically significant.